Catalog No.: PC-20057Not For Human Use, Lab Use Only.
LY3473329 (Muvalaplin) is a potent, specific, multivalent, orally active disruptor/ inhibitor of lipoprotein(a) (Lp(a)) formation, binds to Kringle IV (KIV)8 domain selectively with a potency of 22 nM and inhibits the formation of Lp(a) particles in vitro with IC50 value of 0.09 nM.
LY3473329 (Muvalaplin) is a potent, specific, multivalent, orally active disruptor/ inhibitor of lipoprotein(a) (Lp(a)) formation, binds to Kringle IV (KIV)8 domain selectively with a potency of 22 nM and inhibits the formation of Lp(a) particles in vitro with IC50 value of 0.09 nM.
LY3473329 (Muvalaplin) reduced the levels of Lp(a) with an absolute ED50 of 3 mg kg−1, with a maximum Lp(a) reduction of 92% after five days of BID oral dosing in Lp(a) transgenic mouse model.
LY3473329 (Muvalaplin) is a potent and specific orally administered agent for reducing the levels of Lp(a).
